A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.
- Published In:
- Reviews in endocrine & metabolic disorders, 23(5), 979-994 (2022)
- Authors:
- Aroda, Vanita R(4), Blonde, Lawrence, Pratley, Richard E(4)
- Database ID:
- RPEP-05988
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-05988APA
Aroda, Vanita R; Blonde, Lawrence; Pratley, Richard E. (2022). A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.. Reviews in endocrine & metabolic disorders, 23(5), 979-994. https://doi.org/10.1007/s11154-022-09735-8
MLA
Aroda, Vanita R, et al. "A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.." Reviews in endocrine & metabolic disorders, 2022. https://doi.org/10.1007/s11154-022-09735-8
RethinkPeptides
RethinkPeptides Research Database. "A new era for oral peptides: SNAC and the development of ora..." RPEP-05988. Retrieved from https://rethinkpeptides.com/research/aroda-2022-a-new-era-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.